Skip to main content
SpringerLink
Log in

IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: Focus on gatifloxacin

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The majority of the 1.1 million patients hospitalized for community-acquired pneumonia (CAP) in the United States begin therapy with an intravenous antibiotic. A switch to oral therapy as soon as patients are clinically stable reduces the length of hospitalization and associated costs. Fluoroquinolones are appropriate candidates for switch therapy. Gatifloxacin is an excellent choice when a fluoroquinolone is being considered for sequential switch therapy in the treatment of CAP requiring hospitalization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia.Clin Ther. 1998;20:820–837.

    Article  PubMed  CAS  Google Scholar 

  2. Bartlett JG, Dowel SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults.Clin Infect Dis. 2000;31:347–382.

    Article  PubMed  CAS  Google Scholar 

  3. Sevinç F, Prins JM, Koopmans RP, et al. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital.J Antimicrob Chemother. 1999;43:601–606.

    Article  PubMed  Google Scholar 

  4. Niederman MS, Mandell LA, Anyueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.Am J Respir Crit Care Med. 2001;163:1730–1754.

    PubMed  CAS  Google Scholar 

  5. Press R. The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.Pharmacotherapy. 2001;21:100S-104S.

    Article  PubMed  CAS  Google Scholar 

  6. Ramirez JA. Switch therapy in adults patients with pneumonia.Clin Pulm Med. 1995;2:327–333.

    Article  Google Scholar 

  7. Siegel R. Strategies for early discharge of the hospitalized patient with community-acquired pneumonia.Clin Chest Med. 1999;20:599–605.

    Article  PubMed  CAS  Google Scholar 

  8. Paladino JA. Pharmacoeconomics of antimicrobial therapy.Am J Health-Syst Pharm. 1999;56: S25-S28.

    PubMed  CAS  Google Scholar 

  9. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics.Am J Med. 1991;91:462–470.

    Article  PubMed  CAS  Google Scholar 

  10. Grasela TH, Paladino JA, Schentag JJ, et al. Clinical and economic impact of oral ciprofloxacin as follow-up to parental antibiotics.Ann Pharmacother. 1991;25:857–862.

    Google Scholar 

  11. Fliegelman RM, Mattingly PM, Dempsey CL, Sokalski SJ. Economic impact of oral ciprofloxacin following standard intravenous therapy.Diagn Microbiol Infect Dis. 1990;13:187–199.

    Article  PubMed  CAS  Google Scholar 

  12. Partsch D, Paladino JA. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy.Ann Pharmacother. 1997;31:1137–1145.

    PubMed  CAS  Google Scholar 

  13. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.Chest. 2001;119:1439–1448.

    Article  PubMed  CAS  Google Scholar 

  14. Ball P. Future of the quinolones.Semin Respir Infect. 2001;16:215–224.

    Article  PubMed  CAS  Google Scholar 

  15. Bertino JS. Integrating fluoroquinolones into the hospital formulary.Pharmacotherapy. 2001;21: 273S-283S.

    Article  PubMed  CAS  Google Scholar 

  16. Sahm DF, Peterson DE, Critchley IA, Thornsberry C. Analysis of ciprofloxacin activity againstStreptococcus pnemnoniae after 10 years of use in the United States.Antimicrob Agents Chemother. 2000;44:2521–2524.

    Article  PubMed  CAS  Google Scholar 

  17. Pickerill KE, Paladino JA, Schentag JJ. Reviews of therapeutics.Pharmacotherapy. 2000;20:417–428.

    Article  PubMed  CAS  Google Scholar 

  18. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new ‘respiratory quinolones.’J Antimicrob Chemother. 1999;43(suppl B):l-ll.

    Google Scholar 

  19. Fung-Tomc J, Minassian B, Kolek B, Asho T, Huczko E, Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.Br Soc Antimicrob Chemother. 2000;45:437–446.

    Article  CAS  Google Scholar 

  20. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AG. Antimicrobial resistance among clinical isolates ofStreptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995.Antimicrob Agents Chemother. 2001;45:1721–1729.

    Article  PubMed  CAS  Google Scholar 

  21. Chen DK, McGreer A, de Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network. Decreased susceptibility ofStreptococcus pneumoniae to fluoroquinolones in Canada.N Engl J Med. 1999;341:233–239.

    Article  PubMed  CAS  Google Scholar 

  22. Ho PL, Que TL, Tsang DNC, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains ofStreptococcus pneumoniae in Hong Kong.Antimicrob Agents Chemother. 1999;43:1310–1313.

    PubMed  CAS  Google Scholar 

  23. CDC. Resistance of Streptococcus pneumoniae to fluoroquinolones—United States, 1995–1999.MMWR. 2001;50:800–804.

    Google Scholar 

  24. Martin SJ, Jung R, Garvin CG. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.Drug Saf. 2001;24:199–222.

    Article  PubMed  CAS  Google Scholar 

  25. Blondeau JM, Laskowski R, Bjarnason J, Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 gram-negative and gram-positive organisms.Int f Antimicrob Agents. 2000;14:45–50.

    Article  CAS  Google Scholar 

  26. Smayevsky J, Lopez H, Di Chiara M, et al. Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection.Diagn Microbiol Infect Dis. 2000;37:261–264.

    Article  PubMed  CAS  Google Scholar 

  27. Hershberger E, Rybak M. Activities of trovafloxacin, gatifloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistantStreptococcus pneumoniae in an in vitro infection model.Antimicrob Agents Chemother. 2000;44:598–601.

    Article  PubMed  CAS  Google Scholar 

  28. Coyle EZ, Kaatz GW, Rybak MJ. Activities of newer fluoroquinolones against ciprofloxacin-resistantStreptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:1654–1659.

    Article  CAS  Google Scholar 

  29. Piddock LJ, Johnson M, Ricci V, Hill SL. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.Antimicrob Agents Chemother. 1998;42:2956–2960.

    PubMed  CAS  Google Scholar 

  30. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance inStreptococcus pneumoniae, Haemophilus influenzae, andMoraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999.Clin Infect Dis. 2001; 32:S81-S93.

    Article  PubMed  CAS  Google Scholar 

  31. Blondeau J, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates ofStreptococcus pneumoniae.Antimicrob Agents Chemother. 2001;45:433–438.

    Article  PubMed  CAS  Google Scholar 

  32. Schmitz FJ. Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.Antimicrob Agents Chemother. 2001;45:2666–2667.

    Article  PubMed  CAS  Google Scholar 

  33. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.N Engl J Med. 2002;346:747–750.

    Article  PubMed  Google Scholar 

  34. Kays MB, Smith DW, Wack MF, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistantStreptococcus pneumoniae pneumonia.Pharmacotherapy. 2002;22:395–399.

    Article  PubMed  Google Scholar 

  35. Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistantStreptococcus pneumoniae associated with levofloxacin therapy.J Infect Dis. 2001; 184:794–798.

    Article  PubMed  CAS  Google Scholar 

  36. Empey PE, Jennings HR, Thornton AC, Rapp RP, Evans ME. Levofloxacin failure in a patient with pneumococcal pneumonia.Ann Pharmacother. 2001;35:687–690.

    Article  PubMed  CAS  Google Scholar 

  37. Fish DN, North DS. Gatifloxacin, an advanced 8-methoxy fluoroquinolone.Pharmacotherapy. 2001; 21:35–59.

    Article  PubMed  CAS  Google Scholar 

  38. Culley CM, Lacy MK, Klutman N, Edwards B. Moxifloxacin: clinical efficacy and safety.Am J Health-Syst Pharm. 2001;58:379–388.

    PubMed  CAS  Google Scholar 

  39. Fukuda H, Kishii R, Takei M, Hosaka M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity againstStreptococcus pneumoniae.Antimicrob Agents Chemother. 2001;45:1649–1653.

    Article  PubMed  CAS  Google Scholar 

  40. Fung-Tomc J, Gradelski E, Huczko E, Minassian B, Bonner DP. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.Int J Antimicrob Agents. 2001;18:77–80.

    Article  PubMed  CAS  Google Scholar 

  41. Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.Clin Pharmacokinet. 2001;40:169–187.

    Article  PubMed  CAS  Google Scholar 

  42. Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections?Int J Antimicrob Agents. 2001;17:331–341.

    Article  PubMed  CAS  Google Scholar 

  43. Owens RC. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.Pharmacotherapy. 2001;21:301–319.

    Article  PubMed  CAS  Google Scholar 

  44. Iannini PB, Kubin R, Reiter C, Tillotson G. Reassuring safety profile of moxifloxacin [correspondence].Clin Infect Dis. 2001;32:1112–1114.

    Article  PubMed  CAS  Google Scholar 

  45. Iannini PB, Tillotson GS. Reply to Moxifloxacin does increase the corrected QT interval [correspondence].Clin Infect Dis. 2001;33:1441–1444.

    Article  Google Scholar 

  46. Fogarty C, Grossman C, Williams J, Haverstock D, Church D for the Community-Acquired Pneumonia Study Group. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia.Infect Med. 1999;16:748–763.

    Google Scholar 

  47. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J, the CAPS Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.Chest. 2001;119:185–195.

    Article  PubMed  CAS  Google Scholar 

  48. Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone.Clin Infect Dis. 2000; 31(suppl 2):S51-S58.

    Article  PubMed  CAS  Google Scholar 

  49. Huczko E, Conetta B, Bonner D, et al. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997–1998.Int J Antimicrob Agents. 2000;16:401–405.

    Article  PubMed  CAS  Google Scholar 

  50. Hoellman DB, Lin G, Jacobs MR, Appelbaum PC. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.J Antimicrob Chemother. 1999;43: 645–649.

    Article  PubMed  CAS  Google Scholar 

  51. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.Antimicrob Agents Chemother. 2000;44:2600–2603.

    Article  PubMed  CAS  Google Scholar 

  52. LaCreta FP, Kaul S, Kollia GD, Duncan G, Randall D, Grasela DM. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults.Pharmacotherapy. 2000;20:59S-66S.

    Article  PubMed  CAS  Google Scholar 

  53. Honeybourne D, Banerjee D, Andrews J, Wise R. Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.J Antimicrob Chemother. 2001;48:63–66.

    Article  PubMed  CAS  Google Scholar 

  54. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones.Pharmacotherapy. 2001;21:233S-252S.

    Article  PubMed  CAS  Google Scholar 

  55. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics againstStreptococcus pneumoniae.Diagn Microbiol Infect Dis. 2000;38:151–157.

    Article  PubMed  CAS  Google Scholar 

  56. Kays MB, Conklin M. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates ofStreptococcus pneumoniae.Pharmacotherapy. 2000;20: 1310–1317.

    Article  PubMed  CAS  Google Scholar 

  57. Sullivan JG, McElroy AD, Honsinger RW, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin.J Respir Dis. 1999;20(suppl 11):S49-S59.

    Google Scholar 

  58. Fogarty C, Dowell ME, Ellison WT, Vrooman PS Jr, White BJ, Mayer H. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin.J Respir Dis. 1999;20(suppl 11):S60-S69.

    Google Scholar 

  59. Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation 8-methoxy fluoroquinolone.J Respir Dis. 1999;20(suppl 11):S70-S76.

    Google Scholar 

  60. Von Seggern K, Russo R, Wikler MA. A novel approach to postmarketing surveillance: the Tequin Clinical Experience Study. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto, Ontario, Canada.

  61. Grasela DM, LaCreta FP, Kollia GD, Randall DM, Uderman HD. Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers.Pharmacotherapy. 2000;20:330–335.

    Article  PubMed  CAS  Google Scholar 

  62. Henann NE, Zambie MF. Gatifloxacin-associated acute hepatitis.Pharmacotherapy. 2001;21: 1579–1582.

    Article  PubMed  CAS  Google Scholar 

  63. Coleman CI, Spencer JV, Chung JO, Reddy P. Possible gatifloxacin-induced fulminant hepatic failure.Ann Pharmacother. 2002;36:1162–1167.

    Article  PubMed  Google Scholar 

  64. Lober S, Ziege S, Rau M, et al. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.Antimicrob Agents Chemother. 1999;43:1067–1071.

    PubMed  CAS  Google Scholar 

  65. Iannini PB, Circiumaru I. Gatifloxacin-induced QTc prolongation and ventricular tachycardia.Pharmacotherapy. 2001;21:361–362.

    Article  Google Scholar 

  66. Ambrose P, Bhavnani SM, Cirincione B, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic/pharmacodynamic analysis of age-related drug exposure. Presented at Infectious Disease Society of America meeting; October 24, 2002; Chicago, III.

  67. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics.Br J Pharmacol. 1996;117:372–376.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 64 Brown Street, 78521, Brownsville, TX

    Lorenzo Pelly M.D.

Authors
  1. Lorenzo Pelly M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pelly, L. IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: Focus on gatifloxacin. Adv Therapy 19, 229–242 (2002). https://doi.org/10.1007/BF02850363

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850363

Keywords

Search

Navigation